Since Peer Schatz took over as CEO in early 2004, Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) has seen its revenues and adjusted operating income grow at CAGRs of 21% and 27%, respectively. Molecular diagnostics has contributed most to this growth, with revenues increasing by nearly 40% in both 2007 and 2008, underpinned by the 2007 acquisition of Digene Corp. In 2008, MDx revenues totaled almost $500 million. Qiagen, with a current